Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin
This article was originally published in The Rose Sheet
Executive Summary
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits. Widely credited as a pioneer that helped create the cosmeceutical category, Strivectin has been warning-free since 2005 when FDA came down on its “Better than Botox?” positioning.
You may also be interested in...
FDA Warning Letter Recipients: Where Are Their Claims Now?
A key component of FDA’s enforcement strategy in the cosmetics space is monitoring companies’ websites for overreaching product claims and issuing warning letters accordingly. Examination of past offenders’ current sites and updated claims offers potential visibility into language the agency will and will not tolerate when it comes to promoting skin-care benefits.
People In Brief: IFRA NA's CEO Search Lands On PCPC Exec; More
Formerly assistant general counsel and currently chair of strategic industry categories at the Personal Care Products Council, Farah Ahmed will start as CEO of the International Fragrance Association North America April 18. More people news in brief.
2015 In Review: Tension Builds At The Regulatory Cosmetic/Drug Divide
FDA continued its crackdown on overreaching cosmetic claims in 2015, issuing nine warnings to cosmetic product marketers, while a draft bill emerged in the US House that would redefine "cosmetic" under federal law to provide companies with greater flexibility. Microbead legislation commanded the most national attention, with President Obama signing the federal Microbead-Free Waters Act to close out the year.